Ensysce Biosciences (NASDAQ:ENSC) Releases Earnings Results

Ensysce Biosciences (NASDAQ:ENSC) posted its quarterly earnings results on Tuesday. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.37, Zacks reports. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 559.68%. The business had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $0.25 million.

Ensysce Biosciences Price Performance

NASDAQ:ENSC traded down $0.07 during midday trading on Thursday, reaching $0.64. The stock had a trading volume of 3,081,125 shares, compared to its average volume of 8,568,815. The stock has a market capitalization of $5.61 million, a P/E ratio of -0.35 and a beta of 0.63. Ensysce Biosciences has a 1-year low of $0.14 and a 1-year high of $2.06. The firm’s fifty day simple moving average is $0.37 and its 200-day simple moving average is $0.45.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.